Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
KTTA vs ENTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ENTX Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–1 Matrix Metrics)
ENTX Overall Winner
6-Pillar Tally: KTTA 2 – 2 ENTX (2 Tie)
Matrix Metrics: KTTA 1 – 5 ENTX
As of Nov 20, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Pasithea Therapeutics Corp. (KTTA) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). KTTA carries a Unified Composite Score of 42.1/100 (HOLD) at $0.48 (N/M Forward P/E, 0.0% operating margin), whereas ENTX carries 47.5/100 (HOLD) at $3.31 (N/M Forward P/E, 0.0% operating margin).
- Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (47.5/100 HOLD vs. KTTA 42.1/100 HOLD) and 0.92β · 53% Vol risk profile, whereas KTTA leads top-line expansion (+1498.1% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About KTTA vs ENTX
KTTA
Pasithea Therapeutics Corp. Common Stock
$0.48
-0.48% 1D
Market Cap
$17.7M
TTM Revenue
$486,559
Forward P/E
N/M
Beta / 30D Vol
0.68β · 185% Vol
Unified Composite Score
42.1
HOLD
Tech 20.0
Fund 40.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
ENTX
Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
$3.31
+0.76% 1D
Market Cap
$571.2M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.92β · 53% Vol
Unified Composite Score
47.5
HOLD
Tech 52.0
Fund 49.0
Flow 72.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (KTTA 2 – 2 ENTX)
1. Valuation Multiples
KTTA
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
36.3x
N/M
2. Growth & Scale
KTTA
Revenue Growth (YoY)
+1498.1%
-100.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$486,559
N/A
Market Cap
$17.7M
$571.2M
3. Profitability & Quality
Tie
Gross Margin
-0.5%
N/A
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-88.8%
-20.3%
4. Balance Sheet & Cash Flow
ENTX
Cash Generation (TTM)
-$18M
-$16M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$1.31 Book/Sh · -88.8% ROE
$265M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ENTX
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
116.0% (33rd %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Distribution
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: KTTA (1) vs ENTX (5)| Institutional Metric | KTTA | ENTX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $17.7M | $571.2M | ENTX | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +1498.1% | -100.0% | KTTA | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -88.8% | -20.3% | ENTX | |
| 52-Week Range Position | 11% ($0–$2) | 73% ($1–$4) | ENTX | |
| Beta / 30D Volatility | 0.68β · 185% Vol | 0.92β · 53% Vol | ENTX | |
| Unified Institutional Score | 42.1 / 100 (HOLD) | 47.5 / 100 (HOLD) | ENTX | |
| Trailing 12M Revenue (USD) | $486,559 | N/A | Scale | |
| Gross Profit Margin (TTM) | -0.5% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 36.3x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$18M ($1.31 Book/Sh · -88.8% ROE) | -$16M ($265M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ENTX +1.92 pp
3M Horizon
ENTX +1.85 pp
6M Horizon
ENTX +198.12 pp
1Y Horizon
ENTX +24.13 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | KTTA Revenue | ENTX Revenue | KTTA Op. Margin | ENTX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | N/A | $0M | N/A | -3059.7% | ENTX |
| FY2021 | $0M | $0M | -29925.7% | -2139.6% | ENTX |
| FY2022 | $0M | $0M | -2587.3% | -9714.2% | KTTA |
| FY2024 | N/A | $0M | N/A | -5295.6% | ENTX |
| FY2025 | N/A | $0M | N/A | -27450.0% | ENTX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
KTTA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact KTTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ENTX
CONSOLIDATION
Current IV
116.0%
IV Percentile
33rd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
KTTA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ENTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ KTTA vs ENTX Key Questions & Quantitative Answers
As of Nov 20, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Pasithea Therapeutics Corp. (KTTA) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). KTTA carries a Unified Composite Score of 42.1/100 (HOLD) at $0.48 (N/M Forward P/E, 0.0% operating margin), whereas ENTX carries 47.5/100 (HOLD) at $3.31 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (47.5/100 HOLD vs. KTTA 42.1/100 HOLD) and 0.92β · 53% Vol risk profile, whereas KTTA leads top-line expansion (+1498.1% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KTTA leads the Growth & Scale pillar: KTTA posts +1498.1% YoY revenue growth and +0.0% YoY earnings growth on $486,559 TTM revenue (-0.5% gross margin, 0.0% operating margin), compared with ENTX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 5-period historical trajectory (FY2020 to FY2025), KTTA cumulative revenue shifted N/A while ENTX shifted N/A. In operating R&D and SG&A reinvestment, KTTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTX.
KTTA screens cheaper on headline valuation multiples. KTTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 36.3x EV/Revenue (unreported FCF margin), whereas ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KTTA (-88.8% ROE) versus ENTX (-20.3% ROE) capital efficiency.
In options market volatility and institutional positioning, KTTA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 185% Vol realized risk). By comparison, ENTX carries 116.0% implied volatility (33rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 53% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ENTX vs KTTA · Reverse Pair
KTTA vs QNRX
· Sector Peer
ENTX vs IMMP
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal